Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
Open Access
- 3 September 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Cell Discovery
- Vol. 6 (1), 1-4
- https://doi.org/10.1038/s41421-020-00199-1
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology of the People’;s Republic of China (2020YFC0845900)
- Chinese Academy of Sciences (XDB29040300)
This publication has 10 references indexed in Scilit:
- A human monoclonal antibody blocking SARS-CoV-2 infectionNature Communications, 2020
- COVID-19 vaccine design: the Janus face of immune enhancementNature Reviews Immunology, 2020
- SARS-CoV-2 Vaccines: Status ReportImmunity, 2020
- The SARS-CoV-2 Vaccine Pipeline: an OverviewCurrent Tropical Medicine Reports, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Prospects for a MERS-CoV spike vaccineExpert Review of Vaccines, 2018
- Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequenceVaccine, 2017
- Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccinesEmerging Microbes & Infections, 2012
- A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in miceVaccine, 2010
- Vaccine-induced enhancement of viral infectionsVaccine, 2009